Document is current
Any future updates will be listed below
-
Authors
Sandor, Cynthia https://orcid.org/0000-0002-8905-1052
Millin, Stephanie
Dahl, Andrew
Schalkamp, Ann-Kathrin
Lawton, Michael
Hubbard, Leon
Rahman, Nabila
Williams, Nigel
Ben-Shlomo, Yoav
Grosset, Donald G.
Hu, Michele T.
Marchini, Jonathan
Webber, Caleb
-
Funding
Funding for this research was provided by:
Wellcome Trust (090532/Z/09/Z)
Medical Research Foundation (91070)
- License Information
-
More Information
Article History
Received: 16 February 2022
Accepted: 21 October 2022
First Online: 16 November 2022
Declarations
:
: <i>Oxford Discovery cohort</i>: The clinical data were supplied by the OPDC study. This study was undertaken with the understanding and written consent of each subject, with the approval of the local NHS ethics committee (National Research Ethics Service (NRES) Committee South Central – Oxford A (Ref:16/SC/0108) and Oxford C (Ref:15/SC/0117); Berkshire Research Ethics Committee (Ref: 10/H0505/71)), and in compliance with national legislation and the Declaration of Helsinki.<i>Tracking UK</i>: The study is carried out in accordance with the Declaration of Helsinki and has been described in detail by Malek et al. [].<i>PPMI</i>: As described by Marek et al. [] This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines after approval of the local ethics committees of the participating sites.
: Not applicate.
: J.M. owns stocks and stock options in Regeneron Pharmaceuticals. The remaining authors declare that they have no competing interests.
